Antispasmodic compositions and methods for treating spasticity using negative pressure therapy
Negative pressure therapy combined with antispasmodic compositions effectively treats spasticity by improving blood flow and nerve signal modulation, reducing spasticity frequency and severity, and enhancing overall neurological function.
Patent Information
- Application Number
- JP2022579117
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-22
- Filing Date
- 2021-06-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-06-22
AI Technical Summary
Current treatments for spasticity associated with neurodegenerative diseases like multiple sclerosis (MS) are inadequate, often causing significant side effects and failing to address the underlying causes, leading to progressive muscle stiffness, spasms, and impaired mobility.
Applying negative pressure therapy in conjunction with antispasmodic compositions to reduce spasticity by enhancing blood flow, oxygenation, and modulating nerve signals, thereby reducing the frequency and severity of spastic episodes.
The combination of negative pressure therapy and antispasmodic compositions significantly reduces spasticity, improves neurological function, and enhances patient compliance without increasing harmful side effects, offering systemic improvements beyond the treated area.
Smart Images

Figure 0007586521000006 
Figure 0007586521000001 
Figure 0007586521000002
Abstract
Description
[Technical field]
[0001] The present disclosure generally relates to methods, compositions, and related devices for treating neurodegenerative diseases and associated symptoms, including treatment of spasticity and / or prevention of spasticity and pain. The methods, compositions, and devices may be configured to include applying negative pressure to a patient's body to ameliorate spasticity and pain in the patient's body and / or prevent future episodes of spasticity and pain in the patient's body, as well as to improve neurological symptoms of the neurodegenerative disease. [Background technology]
[0002] Spasticity is a common symptom of injuries and diseases that affect the central nervous system, including brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis (MS), and additional neurodegenerative diseases. The term spasticity is generally used to refer to involuntary and sustained contraction of muscles, such as those associated with muscle stiffness, cramps, excessive movements and reflexes, clonus, or spasms, and is a major cause of disability in individuals with central nervous system injury.
[0003] As a particular example, MS is a chronic disease of the nervous system commonly referred to as an immune-mediated disease in which the immune system is believed to mistakenly attack the central nervous system and can damage the protective myelin sheath around nerve fibers, the oligodendrocytes, and / or the underlying nerve fibers. The resulting demyelination, inflammation, and damage to nerve fibers can cause a variety of symptoms, including spasticity, fatigue, muscle weakness, visual impairment, unsteady gait, numbness, tingling, dizziness, depression, pain, and several others.
[0004] While symptoms of MS are unpredictable and vary from patient to patient and over time within a patient, the majority of patients experience a steady progression of symptoms over time. Currently, there is no recognized cure for MS, and known treatments are generally directed only at slowing the progression of the disease and / or worsening of symptoms.
[0005] Spasticity is one of the most prevalent and distressing of all MS symptoms and is not fully understood, but is generally believed to occur when muscle coordination by the nervous system is impaired in MS patients, causing too many muscles or inappropriate muscles to involuntarily contract. In mild cases, spasticity may only be noticeable as a feeling of tightness, muscle stiffness, pain, or increased muscle tone, but spasticity is often progressive and can escalate into fixed limbs, contracted joints, painful spasms, or other uncontrollable muscle contractions over time.
[0006] Spasticity can generally impede any aspect of mobility, including both involuntary and voluntary movements.While it is uncertain how the symptoms of MS are related, it is believed that spasticity may contribute to or otherwise aggravate other symptoms and complications.For example, spasticity and the associated degeneration of nerves can contribute to the onset and progression of symptoms such as fatigue, muscle weakness, numbness, tingling, dizziness, bedsores, joint pain, and other pains by making normal movement difficult and reducing thousands of small movements that healthy individuals make both while sleeping and while sitting.
[0007] Spasms that occur at night also commonly contribute to sleep deprivation and / or poor sleep quality in MS patients, for example due to spasms that wake the patient during the night or due to tense muscles that prevent the patient from being comfortable enough to sleep, thereby intensifying or causing fatigue, pain, weakness, dizziness and / or depression.
[0008] The manifestation of spasticity itself is also influenced by additional factors or triggers such as sudden movements or changes in position, temperature changes, infections, skin irritation, pain and stress. Unfortunately, the combination of triggers of spasticity and co-morbidities can cause a dangerous worsening and / or escalation of symptoms.
[0009] Overall, as with MS, the primary goal of existing spasticity treatments is to reduce the negative effects as much as possible through physical therapy, medication, electrical stimulation, or surgery. The use of physical therapy to relieve spasticity generally focuses on exercises and movements that can increase flexibility, such as stretching and range of motion exercises, which may be hindered by the need to be careful to avoid inducing spasticity during movement. Unfortunately, physical therapy does not reduce spasticity in all MS patients, and for some, an exercise regimen may be difficult to maintain due to the patient's physical condition, the requirement for additional equipment and management, and the possible induction of increased symptoms.
[0010] The use of pharmacological therapy in treating spasticity often relies on the inhibition or modulation of nerve signals, temporarily replacing the effects of spasticity with other, less severe side effects. For example, baclofen and tizanidine are two drugs that reduce spasticity by attenuating pathologically overactive mono- or poly-spinal reflex arcs in the spinal cord, or by inhibiting spinal and supraspinal reflexes through pre-spinal inhibition. These actions may cause relaxation of both normal and spastic muscles, replacing the specific pain and contractions commonly associated with spasticity with the general drowsiness and muscle weakness associated with pharmacological therapy.
[0011] The use of drug therapy becomes particularly difficult as symptoms progress, because the increased doses required to achieve the same relief from spasticity cause increasingly greater side effects.As such, treatment with drugs and chemical compositions must be based on balancing the positive and negative effects of drugs, and this balance can be difficult to maintain due to the moment-to-moment changes in the intensity of spasticity and the progression of symptoms over time.
[0012] Electrical stimulation therapy and surgical interventions are specifically focused on the direct management and inhibition of nerve fibers in MS patients. Electrical stimulation is used on nerves to affect the way signals are transmitted to the brain, potentially relieving pain, but the positive effects are not well established and are limited to reducing pain without reducing the occurrence of spasticity. Surgical treatments require cutting nerve roots or tendons for permanent relief of spasticity, resulting in severe and permanent side effects. While surgical interventions do not cause the patient to suffer from spasticity in the targeted muscles, they do lose substantial control or utility of those same muscles while the neurodegeneration persists in the body.
[0013] Although not identical, the occurrence of spasticity associated with brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, and other diseases or injuries of the nervous system is similarly difficult to treat or otherwise alleviate, as is the occurrence of spasticity associated with MS. A general effort to alleviate spasticity employs some combination of the above-mentioned treatments with the aim of reducing the pain and discomfort associated with spasticity, but no treatment has been recognized to show substantial reversal of the underlying spasticity itself. The treatment plan for a particular patient must also be closely monitored and adjusted to compensate for the progression of the patient's spasticity and the changing side effects of the treatment.
[0014] There remains a need for a method of treating spasticity with reduced side effects. An ideal treatment would achieve not only a reduction in the pain and difficulty associated with spasticity, but also a reduction in the frequency and severity of its episodes, and a reduction in the associated impairment to motor control. In particular, a treatment that can address the underlying factors that cause spasticity, such as nerve damage and / or loss of voluntary muscle control, would be desirable. By addressing the underlying causes of spasticity rather than treating only pain symptoms, further improvements in mobility and overall quality of life can be achieved for patients who previously had no hope of such improvements.
[0015] Existing treatments for spasticity and related neurodegenerative diseases would benefit from therapeutic approaches that alleviate, halt, or reverse the progression of degeneration in the nerves. There is a need for therapeutic approaches that can improve the effectiveness of existing drug and physical therapy treatments, such as by synergistically improving nerve function in muscles and spinal cord, to reduce dosage levels and associated side effects.
[0016] Additionally, there is a need for simple solutions that can be implemented without increasing the level of intervention required by caregivers or medical professionals, while still being adaptable to the specific needs and symptoms of a given patient. Such treatments and solutions would clearly improve spasticity treatments and solutions over the current state of the art, particularly in patients who have suffered injuries or diseases affecting the central nervous system, including brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, and MS. Summary of the Invention
[0017] The present disclosure includes the discovery that patients suffering from spasticity associated with a disease or injury to the central nervous system can be treated with negative pressure therapy. Surprisingly, it has been found that when negative pressure therapy according to embodiments of the present disclosure is applied to patients suffering from spasticity, the duration, intensity and frequency of spasticity can be significantly reduced. Embodiments of the present disclosure further discover new and unexpected improvements in spasticity and associated symptoms from the combination of negative pressure therapy with existing drug therapy in a treatment regimen. The combination of negative pressure therapy with drug therapy surprisingly reduces the occurrence of side effects from drug therapy and allows for a lower effective dose of the drug. Surprisingly, these improvements have been shown across multiple conditions and multiple drug ranges.
[0018] An object of the present disclosure is to treat spasticity and related conditions, including involuntary and sustained contraction of muscles, such as those associated with muscle stiffness, clamping, excessive movements and reflexes, clonus, or spasms, particularly in patients suffering from central nervous system injury and disease. The present disclosure also relates to methods of administering negative pressure therapy to treat spasticity.
[0019] The present disclosure describes the association between increased blood flow, increased tissue oxygenation, and repeated changes in sensory feedback resulting from negative pressure therapy and reduced intensity, duration, and frequency of spasticity.
[0020] According to embodiments described herein, negative pressure therapy can be applied as a prophylactic measure to prevent the onset of spasticity, as immediate treatment for spasticity that a patient has previously experienced or is currently experiencing, or as part of a comprehensive and formal treatment plan for patients with underlying conditions that may result in spasticity (e.g., MS, brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, etc.).
[0021] A first aspect of the present invention provides a method for treating or preventing spasticity in a patient, comprising administering negative pressure therapy to the patient. The method may further comprise the use or administration of a pharmaceutical composition in combination with the regular administration of negative pressure therapy. Such pharmaceutical compositions may include antispasmodic compositions or others known for their neurological effects, including baclofen, tizanidine, gabapentin, diazepam, nabiximols, dantrolene, clonidine, cannabinoids (OCE, THC, Sativex, etc.), corticosteroids, cytoxan, imuran, ampyra, additional interferon beta drugs, and other drugs that will be understood by those skilled in the art from this disclosure. Additional pharmaceutical compositions such as ocrelizumab, glatiramer acetate (Copaxone, Glatopa), or other immunosuppressive compositions may benefit from the combination with negative pressure therapy in a treatment regime (albeit in a different way).
[0022] In embodiments, a pressure therapy device may be specifically positioned over a limb or region of a patient's body to apply pressure therapy to a user. The limb or region of the patient's body to receive negative pressure may be selected as corresponding to or near an episode of spasticity. The pressure therapy device may be configured to apply negative pressure to the limb or region of the patient's body at a predetermined level of pressure for a predetermined period of time.
[0023] In accordance with the present disclosure, negative pressure therapy can be applied to the extremity of the limb having or exhibiting spasticity, or the extremity of the limb most closely associated with the site of spasticity. Although embodiments contemplate negative pressure therapy being applied to only one limb, the present disclosure is not so limited and can include sequential and / or simultaneous application of pressure therapy to one or more regions of the patient's body.
[0024] Surprisingly, it has been discovered that application of negative pressure therapy according to embodiments of the present disclosure can result in a general reduction in spasticity in a patient's body, even when negative pressure therapy is applied only to a particular limb or limbs. A generalized improvement in symptoms demonstrates a substantial improvement in neurological function and / or health beyond the limb, region or area of the body that receives negative pressure therapy according to the present disclosure.
[0025] Negative pressure therapy according to embodiments of the present disclosure may include application of pulsating or intermittent pressure. Pulsating pressure may include generating negative pressure during a first time interval and releasing the negative pressure during a second time interval. The release of negative pressure during the second time interval may be configured to apply a pressure different from the negative pressure during the first time interval, such as a different negative pressure, atmospheric pressure, environmental pressure, or positive pressure. The first time interval may be longer, the same length, or shorter than the second time interval.
[0026] In embodiments of the method, the duration of application of negative pressure therapy to the patient may be limited to the duration of symptoms or may be configured to a predetermined period of time based on the patient's needs. The frequency of application of negative pressure may be limited to the frequency of symptoms or may be configured to a predetermined schedule based on the patient's needs. In one example, negative pressure may be applied periodically before sleep, upon awakening, and / or upon the occurrence of known spasticity triggers. Alternatively, negative pressure therapy according to the present disclosure may be applied based on a regular schedule, such as daily or twice a day. Negative pressure therapy may be applied at the same time every day, every other day, or every week as part of a regular schedule of treatment. It is noted that regular application of negative pressure therapy does not preclude additional applications on demand or by modifying the regular treatment schedule over time, e.g., by reducing the frequency as symptoms improve.
[0027] It has been found that treating spasticity with negative pressure therapy according to the present disclosure advantageously provides a simple and adaptable method for substantially reducing or preventing spasticity according to the needs of the individual patient. The method of the present disclosure has been found to rapidly treat existing indications of spasticity while reducing future episodes and their severity. Surprisingly, it has been shown that the benefits of the method including negative pressure therapy according to the present application are not only for the symptoms of spasticity, but extend to additional symptoms of neurodegenerative diseases, resulting in a systemic improvement for the patient.
[0028] The disclosed methods advantageously provide benefits to both affected and unaffected areas of the body, while reducing side effects associated with co-applied pharmaceutical compositions or treatments, without introducing any new adverse side effects, and advantageously improve patient compliance and outcomes. While not fully understood, treatment of spasticity with negative pressure therapy may also improve other symptoms associated with MS, associated diseases and / or damaged central nervous system, at least due to the interrelated evolution of the above symptoms.
[0029] The disclosed methods can be applied simultaneously or sequentially with other known treatments or therapies for spasticity or known methods for reducing factors inducing spasticity. Advantageously, the application of negative pressure therapy, particularly in concert with a pharmaceutical composition, enhances the efficacy of the pharmaceutical composition while reducing its associated side effects, such as by reducing the effective dosage.
[0030] Negative pressure therapy according to the present disclosure may be supplemented with heating or cooling units, vibration units, orthotics, braces, electrical stimulation units, and the like.
[0031] In another aspect, the methods of the present disclosure can be applied in conjunction with sensors positioned to monitor the effect of the treatment on the patient and / or tailor the treatment to the patient. For example, blood flow sensors, temperature sensors, electrical sensors, etc. can be used, such as through the use of a control module or other computing device, to monitor the effect of the negative pressure therapy on the patient and adjust the pressure, duration, or other parameters as needed by the patient.
[0032] According to various embodiments, a controller can be provided for operating the pressure therapy device to perform the methods of the present application. The controller can be provided as a mobile device, such as a smart phone, laptop, tablet computer, or similar device. The controller can be arranged to control the application of negative pressure in the pressure therapy device and / or to monitor and report use of the negative pressure device to a clinician or the like to ensure proper treatment or patient compliance.
[0033] These and other features, aspects and advantages of the present disclosure will become better understood with regard to the following description, appended claims, and accompanying drawings. [Brief description of the drawings]
[0034] [Figure 1] 1 shows a perspective view of a pressure therapy device. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] While the present disclosure is susceptible to various modifications and alternative constructions, certain exemplary embodiments are described below, but it should be understood that it is not intended to limit the disclosure to the disclosed embodiments, but rather to cover all modifications, alternative constructions, combinations and equivalents falling within the spirit and scope of the present disclosure and as defined by the appended claims.
[0036] It will be understood that unless a term is defined in this patent as having a stated meaning, there is no intention, explicitly or indirectly, to limit the meaning of such term beyond its common or ordinary meaning.
[0037] Although exemplary embodiments of the present disclosure are described for treating patients experiencing spasticity as a result of MS, embodiments of the present disclosure can also be adapted to treat spasticity resulting from various types and severity of disease or trauma of the central nervous system, as discussed in the background of this application. Similarly, embodiments of the present disclosure can be adapted to treat additional symptoms of MS and related diseases or injuries, such as pain, limited flexibility, fatigue, depression, loss of innervation or sensation in muscles and limbs, whether or not the additional symptoms mentioned above are associated with spasticity. The steps of the method for treating spasticity using negative pressure therapy can be configured as independent steps for treatment or can be easily adapted to be integrated with other treatments or therapies.
[0038] The "antispasmodic composition" according to the present disclosure can include any known pharmaceutical composition used to treat spasticity in injuries or diseases affecting the central nervous system, including brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis (MS) and further neurodegenerative diseases. For example, the antispasmodic composition can include baclofen, tizanidine, gabapentin, diazepam, nabiximols, dantrolene, clonidine, cannabinoids (OCE, THC, Sativex, etc.), corticosteroids, cytoxan, imuran, ampyra, dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), phenibut, additional interferon beta drugs, and similar pharmacological compositions, whether administered by injectable, oral or infusion treatment. The dosage of the antispasmodic composition may be commensurate with the level of skill in the art, but may be further reduced given the benefit of this disclosure.
[0039] Further pharmacological compositions may be considered "immunosuppressant compositions" that act to suppress autoimmune attacks on the nervous system, and may be beneficially combined with negative pressure therapy in a treatment regime, albeit in a different manner than with antispasmodic compositions. Immunosuppressant compositions may include any known pharmacological composition used to treat or prevent relapse in injuries and diseases that affect the central nervous system, including brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis (MS), and further neurodegenerative diseases. For example, the immunosuppressant composition may include ocrelizumab, glatiramer acetate (Copaxone, Glatopa), fingolimod (Gilenya), teriflunomide (Aubagio), siponimod (Mayzent), cladribine (Mavenclad), natalizumab (Tysabri), alemtuzumab (Campath, Lemtrada) or other immunosuppressant pharmacological compositions, whether administered as an injectable, oral, or infusion treatment. The dosage of the immunosuppressant composition may be at the level of one of skill in the art, but may be further reduced given the benefit of the present disclosure.
[0040] The term "morning" is used herein to describe the early hours of the day after a patient awakens from a night's sleep, generally between about 6:00 and 11:00 a.m. In one embodiment, negative pressure therapy may be administered at 8:30 a.m. before or after awakening from a night's sleep. The term "evening" is used herein to describe the later hours of the day before a patient goes to bed at night to sleep, generally between about 7:00 and 10:00 p.m. In one embodiment, negative pressure therapy may be administered at 7:00 p.m. before or after a patient lies down to sleep.
[0041] Reference to a "limb" as used in this disclosure may be any part of the human or animal body that can be readily adapted to a pressure therapy device as described in this disclosure. A limb may include an arm or leg, a portion of an arm or leg (e.g., a forearm, a hand, a lower leg, or a foot), or multiple such parts of the body. Although the pressure therapy device is described in the context of an embodiment directed to the lower leg and foot, many of the features described herein can be extended to pressure therapy devices and components that secure other limbs or body parts to perform the methods of the present disclosure.
[0042] For purposes of explanation, embodiments of the present disclosure may refer to common anatomical terms of the human body. Such anatomical terms are provided to distinguish body parts from one another, but are not intended to limit the scope of the present disclosure. The terms "proximal" and "distal" generally refer to locations that correspond to positions on a limb relative to the limb's point of connection to the torso. The terms "upper" and "lower" may be used in conjunction with "proximal" and "distal" to imply gradual changes in "proximal" and "distal" positions.
[0043] An embodiment of a method of treating or preventing spasticity in a patient is provided for reducing the effects of spasticity or reversing the manifestations of spasticity in the muscles of the patient, the method comprising administering negative pressure therapy to the patient. Further embodiments can include the use of an antispasmodic composition for treating spasticity and associated symptoms in a patient, the negative pressure therapy being administered to the patient to improve the effect of the antispasmodic composition.
[0044] The embodiments of the method advantageously allow for the treatment of spasticity while reducing the need for drugs or invasive surgery and reducing the occurrence of associated side effects. According to various embodiments, in some patients, spasticity can even be treated without the use of drugs or surgical treatments at all. The method further treats spasticity through interaction with both the affected tissue and the corresponding parts of the nervous system, allowing for the treatment of the underlying causes and associated effects of spasticity rather than simply reducing pain. Thus, the disclosed method provides the unexpected results of improved walking ability, improved stability, reduced pain, improved sleep, improved mood, reduced fatigue, and further systemic improvement.
[0045] Further benefits of the described embodiments may include improved peripheral blood flow, healthier arteries, improved endothelial function, reduced lactate, improved mitochondrial activity, and reduced and prevention of chronic inflammation.
[0046] MS and related damage and diseases of the central nervous system that cause spasticity are generally believed to damage the ability of the central nervous system to regulate nerve signals, resulting in involuntary painful contraction or relaxation of muscles.Of the possible causes of spasticity, it is believed that local conditions in the patient's body parts deteriorate, resulting in undesirable opening of ion channels as well as inhibition of degradation, release, or uptake of transmitters.Local conditions may affect sensory endings that transmit or contribute to inappropriate sensory feedback, hypersensitivity, or dysfunctional signals that cause spasticity.
[0047] Without being bound by any theory, it is believed that the unexpected and surprising effectiveness of treating spasticity with negative pressure therapy occurs in part as a result of the generation of repeated changes in sensory feedback from the patient's peripheral nervous system. This sensory input acts on the spinal cord nerve network to affect hyperexcitability of interneurons, motor neurons, or other elements of the central nervous system that contribute to the development of spasticity.
[0048] In particular, the vascular nerves in the veins of the body are activated and vasodilated to a great extent, meaning that the increased blood flow caused by a negative pressure environment has a nearly direct, outsized effect on the sensory input received by the central nervous system. The combined effect of stimulating the vascular nerves, the sensory nerves of the skin, and the nerves of the muscles caused by negative pressure therapy may extend simultaneously over much of the patient's body and / or vasculature such that strong signals or sensory inputs are provided over or within much of the body at regular or intermittent intervals.
[0049] It is believed that the strong intermittent sensory input caused by negative pressure therapy can interrupt dysfunctional or defective nerve signals commonly associated with spasticity, and can unexpectedly enhance the ability of the central nervous system to regulate nerve signals through repeated use.In this way, the sensory input provided by negative pressure therapy can surprisingly help to essentially "reset" parts of the nervous system, particularly those parts associated with spasticity, and / or to effectively "work" these parts of the nervous system to reduce the occurrence of undesirable opening of ion channels, as well as inhibit the degradation, release or uptake of transmitters, improving nerve sensory feedback, sensitivity, and signal function.
[0050] The described beneficial effects on the nervous system can be coordinated with the administration of antispasmodic compositions to achieve surprising combined or synergistic effects on spasticity as well as associated symptoms and conditions. Without being bound by any particular theory, antispasmodic compositions can function by activating or agonizing receptors in the nervous system to reduce the frequency and / or severity of spasticity, and simultaneously improving sensory input and processing associated with the negative pressure therapy of the present disclosure can surprisingly enhance the receptor activation or agonizing effect. The resulting increased effective uptake of the antispasmodic composition can be a product of increased receptor health or coordination, such that the resulting effective dosage and corresponding side effects can be reduced as a result of the combined use of the antispasmodic composition and negative pressure therapy. A summary of some antispasmodic compositions and their associated effects is provided in Table I below (see also Patejdl Robert, Zettl Uwe K., Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions, Autoimmunity Reviews (2017)). TIFF0007586521000001.tif186143
[0051] The use of the antispasmodic composition according to the present disclosure for treating spasticity resulting from MS or related conditions can preferably include the simultaneous application of negative pressure therapy.For example, the antispasmodic composition may be administered to the patient daily according to a result-effective dose and schedule, such that the combination of negative pressure therapy and antispasmodic composition to the patient allows for the administration of a reduced dose to achieve the same or greater benefit while reducing or preventing undesirable side effects.In another example, the negative pressure therapy can be administered to the patient according to a regular schedule, and the antispasmodic composition can be administered to the patient by individual dose escalation, starting with a low dose and gradually increasing until optimal effect is achieved.
[0052] In particular, the use of the antispasmodic composition can reduce the dosage required to be administered to the patient, whether the dosage is reduced from a previous administration level or reduced to a predicted level. The use of the antispasmodic composition for the treatment of MS or related conditions using the application of negative pressure therapy can further exhibit synergistic effects with the antispasmodic composition, such that further improvement of symptoms or even reversal of the progression of symptoms can result.
[0053] Similarly, those skilled in the art who consider the above benefits of the combination of antispasmodic composition and negative pressure therapy will expect the beneficial results that will result from combining the immunosuppressant composition with negative pressure therapy, whether or not the antispasmodic composition is used.The immunosuppressant composition used in treating MS and related conditions helps to inhibit autoimmune attacks on the nervous system, while the simultaneous application of negative pressure therapy according to the method of the present disclosure can help to repair or inhibit damage to the nervous system in light of the above benefits.
[0054] Of particular interest in the use of negative pressure therapy for the treatment of spasticity associated with MS and similar conditions is the effect of increased sensory input on neural networks that normally cause rhythmic activation of muscles to control the limbs, called central pattern generators (CPGs). These generators are generally thought to be influenced by a variety of factors, including sensory input from the peripheral nervous system.
[0055] In patients suffering from MS and related conditions, it is believed that the inhibitory signals (from inhibitory interneurons) that normally limit or restrict the unwanted activity of motor neurons are reduced due to damage to the central nerves, allowing increased activity of motor neurons that activate CPGs and lead to spasticity. It is believed that the strong sensory input resulting from the administration of negative pressure therapy synchronizes and / or enhances the inhibitory effect from inhibitory interneurons such that background motor neuron overactivation or hypersensitivity is prevented. Such synchronization and / or enhancement of the inhibitory effect by inhibitory interneurons may be particularly beneficial to patient populations that rely on antispasmodic compositions for treatment. As discussed above, the surprising improvement in synchronization and / or enhancement of the inhibitory effect by inhibitory interneurons resulting from negative pressure therapy may enhance the corresponding inhibitory or neurological effect of the antispasmodic composition, leading to a faster and more efficient response to the antispasmodic composition in the treatment of spasticity and related conditions.
[0056] Further benefits to patients suffering from spasticity are believed to include an overall increase in peripheral tissue status leading to healthier function. In particular, increased tissue oxygenation and blood flow may allow peripheral tissues to better regulate and control associated transmitters that may otherwise cause contractions associated with spasticity. Additional benefits corresponding to the link between blood flow and spasticity, and the link between peripheral sensory input and spasticity, are anticipated and may be realized by treating spasticity using negative pressure therapy according to the methods of the present disclosure.
[0057] Negative pressure therapy according to embodiments of the present disclosure can include application of pulsating pressure or repeated alternating introduction of two or more different pressures during successive time periods. The pulsating pressure can include generating negative pressure for a first time interval and releasing the negative pressure for a second time interval. The release of negative pressure during the second time interval can be configured to apply a pressure different from the negative pressure of the first time interval, such as a different negative pressure, atmospheric pressure, environmental pressure, or positive pressure. The first time interval can be longer, the same length, or shorter than the second time interval.
[0058] In one example, pulsating pressure can include alternating introduction of applied pressure and release of the applied pressure to return to approximately atmospheric pressure. The applied pressure can be positive or negative. In embodiments using negative pressure, the period during which negative pressure is introduced and creates negative pressure is the negative pressure period. Similarly, in systems using positive pressure, the period during which positive pressure is introduced and creates positive pressure is the positive pressure period. In each case, the time during which the applied pressure is released and atmospheric pressure is returned and creates atmospheric pressure is the atmospheric pressure period.
[0059] The embodiments discussed herein are discussed with reference to the application of negative pressure. This disclosure should not be construed to exclude devices and methods that use positive pressure rather than negative pressure. Furthermore, the disclosed embodiments are not limited to the use of pressure, but can include alternative methods for activating the vasodilator reflex in the body on an intermittent basis.
[0060] In some embodiments, multiple, successive, alternating periods of negative pressure and atmospheric pressure are applied to the limb within the pressure chamber without removing the limb from the chamber. The negative pressure and atmospheric pressure periods can be of the same or different duration. In some embodiments, the negative pressure and atmospheric pressure periods can be selected according to known methods, such as those described in commonly owned U.S. Patent No. 7,833,179, issued Nov. 16, 2010, and incorporated herein by reference in its entirety.
[0061] In some embodiments, the negative pressure period is between 1 and 20 seconds in duration and the atmospheric pressure period is between 2 and 15 seconds in duration, in some embodiments, the negative pressure period is between 5 and 15 seconds in duration and the atmospheric pressure period is between 5 and 10 seconds in duration, and in some preferred embodiments, the negative pressure period is approximately 10 seconds in duration and the atmospheric pressure period is approximately 7 seconds in duration.
[0062] The pressure applied within the pressure chamber can be fixed or selected at the time of use. Embodiments of the apparatus and methods according to the present disclosure comprise applying a negative pressure of -150 mmHg or less, particularly a negative pressure of -80 mmHg (-10.7 kPa) or less. In some embodiments, the negative pressure can be -60 mmHg (-8.0 kPa) or less. Some embodiments use a negative pressure of approximately -40 mmHg (-5.3 kPa).
[0063] The preferred negative pressure is selected to reduce complications that may arise from application of greater negative pressure. In some embodiments, the negative pressure is selected to promote local vasodilation at the surface of the limb while minimizing the risk of potential complications. Pulsating negative pressure has been found to promote blood flow, and preferably, a pulsating negative pressure of 0 to -40 mmHg (0 to -5.3 kPa) is generated in the pressure chamber.
[0064] In one embodiment, negative pressure therapy may include placing a pressure therapy device to apply negative pressure therapy to a patient's body part, for example, a patient's limb, such as a leg or arm. A patient's body part may be selected to receive negative pressure therapy due to the occurrence of spasticity in that part or its proximity to a part of the patient's body experiencing spasticity. In one example, negative pressure therapy may be applied to a patient's leg to treat spasticity occurring in the patient's upper leg or lower back.
[0065] According to embodiments, the pressure therapy device may include any suitable device for applying negative pressure to a part of a patient's body. Figure 1 shows an example of a pressure therapy device 100 from co-owned U.S. Patent No. 10,940,075, issued March 9, 2021, and incorporated herein by reference in its entirety.
[0066] As shown in Figure 1, the pressure therapy device can include a pressure chamber 110. The pressure chamber 110 can be positioned to encase a patient's limb between first and second ends 112, 114 and front and rear sides 116, 118 of the pressure chamber 110. In the embodiment of Figure 1, the second end 114 defines an opening 120 to an interior region 122, 124 inside the pressure chamber 110.
[0067] The interior region 124 of the pressure chamber 110 can be in communication with a pump unit 190 through conduits 188 at the sides 116, 118 of the pressure chamber 110, which is configured to increase and decrease the pressure in the interior regions 122, 124 of the pressure chamber 110. The inflatable pad 140 can grip the patient's limb while the seal 150 is secured to the pressure chamber, surrounding the opening 120 and extending proximally beyond the pressure chamber 110 such that the seal 150 fits tightly around the patient's limb and closes off the pressure chamber 110 from ambient pressure.
[0068] As shown in FIG. 1, the pressure chamber 110 can include a support surface 130 at the second end 114. The support surface 130 can include a flat bottom 132 and an angled portion 134, and can be molded as a separate part that is secured to the pressure chamber 110. The flat bottom 132 allows the pressure chamber 110 to remain stable in a predetermined position so that a user can sit comfortably while using the pressure therapy device 100. The angled portions 134 can be present on the front and rear surfaces 116, 118, allowing the pressure chamber 110 to be stably positioned in an inclined position. The angled portions 134 can be curved to allow the pressure chamber 110 to rotate easily, or can be flat to provide stability in a predetermined position. The limb can then contact a positioning feature 172 in the pressure chamber 110, and the pressure chamber 110 can be rotated to lie on the flat portion of the lower surface 130.
[0069] The support surface 130 may include a modular space 180 for receiving one or more modular components. In one embodiment, the modular components may be replaceable and may include vibration components, heating components, cooling components, etc.
[0070] The seal 150 may have a frusto-conical shape including a proximal end 152 and a distal end 154. The proximal end 152 may have a central axis that is eccentric relative to the central axis of the distal end 154 such that the limb is positioned more posteriorly of the opening 120. When secured around a user's limb, the pull tab 157 may be configured to extend along a distal length of the seal 150 such that the user may grasp and open the seal 150 around the limb. The proximal end 152 of the seal 150 may widen the opening of the seal 150 and unroll distally for limb placement or removal. The protrusions 156 may be positioned on the distal end 154 to frictionally hold the seal 150 in a rolled-up position such that the user does not need to hold the seal 150 down during limb placement. This feature allows for use of the pressure therapy device 100 by individuals who do not have sufficient strength, dexterity, or mobility to manipulate the seal while manipulating the limb or pressure chamber 110.
[0071] According to various embodiments, the pump unit 190 can include or be operatively connected to sensors arranged to monitor the effect of the treatment on the patient and / or tailor the treatment to the patient. For example, blood flow sensors, temperature sensors, electrical sensors, etc. can be used to monitor the effect of the negative pressure therapy on the patient and to adjust the pressure, duration, or other parameters as needed by the patient, such as through the use of a control module or other computing device associated with the pump unit 190. A controller for the pump unit 190 can be provided to operate the pressure therapy device to perform the methods of the present application. The controller can be provided as a mobile device, such as a smart phone, laptop, tablet computer, or similar device within or operatively connected to the pump unit 190. The controller can be arranged to control the application of negative pressure in the pressure therapy device and / or to monitor the use of the negative pressure device and report to a clinician or the like to ensure proper treatment or patient compliance.
[0072] In one embodiment, treatment of spasticity with negative pressure therapy can begin at the first sign of spasticity, which may include increased muscle tone, clamps, spasms or other involuntary muscle contractions, but may also include a tingling sensation or other sensations identified by the patient as preceding or accompanying a contraction in the muscle.
[0073] The duration of negative pressure therapy applied to the patient may correspond to the spasticity the patient is experiencing, with application of negative pressure therapy continuing until the symptoms have completely subsided, or alternatively, a predetermined time beyond the cessation of symptoms may be selected, for example, 5 minutes, 10 minutes, or 20 minutes after the cessation of symptoms.
[0074] In another embodiment of the method, negative pressure therapy may be applied as a preventative measure to prevent the onset of symptoms of spasticity. In one example, a patient may be treated with negative pressure therapy prior to a known trigger of spasticity, including temperature changes or changes in position, or in response to an otherwise uncontrollable trigger of spasticity, such as infection or pain. In one embodiment, periodic treatment of a patient with negative pressure therapy is contemplated, where the patient utilizes negative pressure therapy at least once a day for a period of time.
[0075] The embodiment may also include the use of the antispasmodic composition for the treatment of spasticity or related conditions as described herein. The method may include administering the antispasmodic composition and applying negative pressure therapy to enhance the effect of the antispasmodic composition. In one example, a patient may receive a treatment that includes daily administration of the antispasmodic composition and daily application of the negative pressure therapy according to the present application. The dosage of the antispasmodic composition may be reduced due to the additive or synergistic effect of the composition with the negative pressure therapy. In one aspect, the antispasmodic composition may be administered on demand, such that negative pressure therapy can be applied corresponding to the administration of the antispasmodic composition, such as simultaneously or within the same day.
[0076] In various embodiments, negative pressure therapy may be applied to the patient within 24 hours of administration of the antispasmodic composition to the patient, particularly within 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 3 hours, 1 hour, or at the time of administration of the antispasmodic composition. Administration of the antispasmodic composition may be on a regular schedule, such as after a particular meal, every morning, or every night. Application of negative pressure may be performed simultaneously with administration of the antispasmodic composition, or on a related schedule, such as administration of an antispasmodic drug upon waking and application of negative pressure therapy when lying down to sleep.
[0077] The first administration of the spasmolytic composition may be performed at a result-effective dose and in a result-effective manner as understood by those skilled in the art who have studied this application, but subsequent administrations may be performed at lower doses.For example, the first dose may be administered with negative pressure therapy applied simultaneously for a period of less than 6 months, less than 3 months, less than 1 month, or less than 2 weeks.Therefore, the subsequent lower doses of the spasmolytic composition may be administered 6 months, 3 months, 1 month, or 2 weeks after the first administration and the simultaneous application of negative pressure therapy.
[0078] In one embodiment, negative pressure therapy may be administered to the patient before sleep to prevent the onset of spasticity due to sleep disorder.In another embodiment, negative pressure therapy may be administered to the patient before rising from sleep to prevent the onset of spasticity associated with the initial movement of the patient's muscles and weight bearing.
[0079] Preventive treatment of spasticity using negative pressure therapy can be applied to at least one region of the patient's body for at least 20 minutes, at least 30 minutes, at least 40 minutes, or at least 1 hour. According to some embodiments, preventive treatment can include one treatment per day, two treatments per day, or at least two treatments per day to at least one region of the patient's body. Although embodiments in which negative pressure therapy is applied to only one limb are contemplated, the present disclosure is not limited to such embodiments and can include sequential and / or simultaneous application of pressure therapy to one or more regions of the patient's body.
[0080] The disclosed preventative treatments using negative pressure therapy may be provided as a regular, continuous part of a treatment regimen for the duration of a central nervous system disease or injury, such as MS. In particular, it is possible that the frequency and duration of treatment may be reduced without a corresponding increase in spasticity or related symptoms in some patients, although it is preferred that treatment be applied in a regular, continuous manner to achieve the maximum level of prevention or recovery.
[0081] The disclosed method advantageously provides benefits to both diseased and non-diseased body sites without adverse side effects, improving patient compliance and outcomes. Although not fully understood, treatment of spasticity with negative pressure therapy may also improve other symptoms associated with MS or damaged central nervous system, at least due to the interrelated progression of the above symptoms. Similarly, treatment of spasticity with antispasmodic composition administered with negative pressure therapy may also improve other symptoms associated with MS or damaged central nervous system, at least due to the interrelated effects of the above symptoms, and the benefits of antispasmodic composition and negative pressure therapy.
[0082] As will be appreciated by one of ordinary skill in the art from the present disclosure, the above methods of treating spasticity using negative pressure therapy may be applied simultaneously or sequentially with other known treatments or therapies for spasticity or known methods for reducing the triggers of spasticity. For example, negative pressure therapy according to the present disclosure may be supplemented with heating or cooling units, vibration units, orthotics, braces, electrical stimulation devices, etc.
[0083] In another embodiment, the methods of the present disclosure may be applied using sensors positioned to monitor the effect of the treatment on the patient and / or tailor the treatment to the patient. For example, blood flow sensors, temperature sensors, electrical sensors, etc. may be used, such as through the use of a control module or other computing device, to monitor the effect of the negative pressure therapy on the patient and adjust the pressure, duration, or other parameters as needed by the patient.
[0084] A controller may be provided for operating the pressure therapy device to perform the methods of the present application. The controller may be provided as a mobile device, such as a smart phone, laptop, tablet computer, or similar device. The controller may be arranged to control the application of negative pressure in the pressure therapy device and / or to monitor and report use of the negative pressure device to a clinician or the like to ensure proper treatment or patient compliance.
[0085] In one embodiment, the controller can include a challenge-response module configured to pose a challenge or question to the patient before, during, or after operation of the pressure therapy device. The challenge or question can include information regarding the patient's symptoms or treatment parameters, and the patient's response can be provided to a remote server for further processing, editing, etc. According to various embodiments, a response to the challenge can be required for operation of the pressure therapy device. Further processing or editing of the response at the remote server can be used to determine operating parameters for use by the controller in operation of the pressure therapy device or for providing a recommended treatment or schedule to the patient.
[0086] Multiple case studies have been used to demonstrate the effectiveness of negative pressure therapy according to the present disclosure for treating spasticity, including the use of antispasmodic compositions in combination with negative pressure therapy, with positive initial results.
[0087] In one such case study, negative pressure therapy in the form of pulsating negative pressure was administered to a patient suffering from MS-related spasticity in the form of overnight muscle clamping. The patient presented with a history of severe clamping associated with spasticity in the legs. The clamping typically began slowly and increased in severity as it spread up the limbs over a period of 5-10 minutes. Both legs were usually affected, whether simultaneously or separately. In addition to the impact of the patient's spasticity symptoms, the patient suffered from seizures most frequently at night and an associated poor quality of sleep.
[0088] Prior to treatment with negative pressure therapy, patients had resorted to the use of muscle relaxants or antispasmodic compositions, which generally required at least 20 minutes for pain relief and did not result in a reduction in the frequency of clamping from one day to the next. Although not as severe as clamping, the drugs exhibited common side effects that were preferably avoided.
[0089] Over an initial period of 25 days, negative pressure therapy according to the present disclosure was administered as a preventative treatment for spasticity. The treatment consisted of applying pulsating negative pressure to one or more limbs for periods of 1 hour, 40 minutes, or 30 minutes. The patient recorded the treatment administered and classified the clamping associated with spasticity as mild, moderate, or severe. The duration of the treatment included a period of approximately 8 hours during which no clamping or other effects associated with spasticity were felt in the treated leg during the night. The use of muscle relaxants, or antispasmodic compositions, was reduced in frequency and dosage, showing a reduction in observed side effects without reducing the positive effects.
[0090] In contrast, when negative pressure therapy was not administered, clamping was common, either in both legs or in only one leg, and its severity increased depending on the amount of time that had passed since treatment with negative pressure therapy.Thus, the use of muscle relaxants or antispasmodic compositions was similarly adversely affected, requiring an increasing amount of time for pain relief depending on the amount of time that had passed since treatment with negative pressure therapy.
[0091] The recorded treatment regimens and spasticity clamp classification results are shown below in Table II. TIFF0007586521000002.tif106143 TIFF0007586521000003.tif234146 TIFF0007586521000004.tif35143
[0092] Patients further reported that application of negative pressure therapy to an active spasticity clamp was effective in reducing the clamp in less than 5 minutes, such as during daytime use.
[0093] In another study, the effect of various pressure levels on the user's limbs was analyzed by using the pressure therapy device of the present disclosure to treat a sample population of 16 individuals with peripheral arterial disease, over 90% of the study sample population suffered from mild claudication and were classified as stage II of the Fontaine classification for chronic limb ischemia.
[0094] Pairwise comparisons of the effects of pressure levels -10mmHg, -20mmHg, -40mmHg and -60mmHg on blood flow, and laser Doppler flux measurements of the legs and feet were performed and showed statistically significant increases in blood flow and Doppler flux, as shown in Table III below. TIFF0007586521000005.tif159156
[0095] As has been demonstrated, embodiments of the pressure therapy device using a negative pressure of approximately -40 mmHg (-5.3 kPa) show significant improvement in blood flow through the limbs of patients suffering from peripheral arterial disease.
[0096] As shown in this disclosure, it has surprisingly been found that increasing blood flow and oxygenation can be more effective in reducing and treating spasticity in patients suffering from spasticity associated with injury or disease of the central nervous system. The use of negative pressure therapy according to the disclosed embodiments does not simply provide pain relief or increased muscle relaxation, but has surprisingly shown new and unexpected results of improving neural control in patients suffering from MS or related diseases and injuries affecting the central nervous system. No similar benefit had been achieved or otherwise expected prior to the discoveries disclosed in this application.
[0097] In a further observational study, negative pressure therapy according to the disclosed method was applied to seven patients diagnosed with MS. Of the seven patients, three were specifically diagnosed with secondary progressive MS (SPMS), two were specifically diagnosed with relapsing-remitting MS (RRMS), one was specifically diagnosed with primary progressive MS (PPMS), and one was not specifically diagnosed with a particular category. Each of the patients had previously been treated for their condition with the antispasmodic composition, and use of the antispasmodic composition was continued during the study, although a reduction in dosage was observed in some patients.
[0098] The application of negative pressure therapy according to the disclosed method has favorable results. Six of the seven patients reported problems with spasticity, and four of the six patients (67%) reported that at least stiffness and / or spasm symptoms in the legs improved after negative pressure therapy. Three patients reported problems with clamping in the legs, and two of the three (67%) reported that clamping symptoms improved after negative pressure therapy, while the third did not use treatment based on the parameters of the disclosed method. Five of the patients reported problems with either paresthesia, hypoesthesia (described as numbness) or paresthesia (described as tingling, electric shock, burning or prickling), and four of the five patients reported improvement (80%) after negative pressure therapy.
[0099] Four of the patients reported having problems with some degree of pain in their limbs, and each of the four (100%) reported improvement after negative pressure therapy. Three of the patients reported having problems with fatigue as a prominent symptom of their MS, and two of the three reported improvement in fatigue levels after negative pressure therapy (67%). Four of the patients reported having problems with sleep disturbances and poor sleep quality due to MS symptoms manifested in the legs, and each of the four (100%) reported improvement in sleep quality after negative pressure therapy. Additionally, three of the patients reported improved mood (42%), four of the patients reported improved functionality (57%), and five of the patients reported improved quality of life (71%). The reported improvements are clearly evidence of new and unexpected results from the treatment of MS patients through the application of negative pressure therapy according to embodiments of the present disclosure.
[0100] The above case studies clearly demonstrate the advantages of treating spasticity using negative pressure therapy in accordance with the present disclosure, including preventing spasticity and treating ongoing spasticity, similar advantages never before contemplated or realized in the prior art.
[0101] As is readily apparent from the above discussion, it will be appreciated that the duration, pressure, timing and location of negative pressure therapy and associated devices can be adjusted so that a wide variety of users in different body parts and having different levels of spasticity can benefit from the method. It will also be appreciated that negative pressure therapy according to the present disclosure can be adjusted for use in combination with other known treatments for spasticity.
Claims
1. An antispasmodic composition for use in a method for treating or preventing spasticity in a patient, comprising: The method comprises: administering a resultant effective dose of the antispasmodic composition; and applying negative pressure therapy to the patient. Including, the negative pressure therapy comprising the steps of placing the area of skin of the patient in an enclosure such that the area of skin is sealed from outside conditions; and applying negative pressure to the area of skin with a pressure therapy device; The pressure therapy device comprises: a pressure chamber configured to encase the area of the patient's skin within an interior area and having an opening to the interior area; a seal secured to the pressure chamber to close the pressure chamber from ambient pressure; a pump unit in communication with the interior region and configured to increase and decrease pressure in the interior region; the negative pressure is a pulsating pressure, the pulsating pressure including creating a negative pressure against the area of skin for a first predetermined time interval and releasing the negative pressure for a second predetermined time interval; The spasticity is the result of brain injury, spinal cord injury, cerebral palsy, stroke, fibromyalgia, myalgic encephalomyelitis / chronic fatigue syndrome, neuromyelitis optica, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis (MS), or other neurodegenerative disease; and The antispasmodic composition comprises baclofen, tizanidine, gabapentin, diazepam, nabiximols, dantrolene, or clonidine.
2. The antispasmodic composition of claim 1 , wherein the administering step follows detection of increased spasticity in the patient.
3. The antispasmodic composition according to claim 1 or 2, wherein the negative pressure is between -20 mmHg and -80 mmHg.
4. The antispasmodic composition according to any one of claims 1 to 3, wherein the first predetermined time interval is different from the second predetermined time interval.
5. The antispasmodic composition according to any one of claims 1 to 4, wherein the first and second predetermined time intervals each have a duration greater than a heart rate of the patient.
6. The antispasmodic composition of any one of claims 1 to 5, wherein the area of the patient's skin corresponds to a spasticity in the patient.
7. The antispasmodic composition according to any one of claims 1 to 6, wherein the step of applying negative pressure therapy to the patient comprises treatment for at least 30 minutes.
8. The antispasmodic composition of claim 7 , wherein the step of applying negative pressure therapy to the patient includes treatment for at least 40 minutes.
9. The antispasmodic composition of claim 8 , wherein the step of applying negative pressure therapy to the patient comprises at least one hour of treatment.
10. The antispasmodic composition according to any one of claims 1 to 9, wherein the step of applying negative pressure therapy to the patient comprises at least two treatments per day.
11. The antispasmodic composition according to any one of claims 1 to 10, wherein the applying and / or administering step is applied before the patient sleeps.
12. The antispasmodic composition according to any one of claims 1 to 11, wherein the applying step is performed on at least two limbs of the patient.
13. the applying step includes applying an effective amount of negative pressure therapy to the patient's limb; The limb is the limb affected by spasticity or closest to the area of spasticity. The antispasmodic composition according to any one of claims 1 to 12.
14. The antispasmodic composition according to any one of claims 1 to 13, wherein the spasticity is the result of multiple sclerosis (MS).
15. An antispasmodic composition described in any one of claims 1 to 14, wherein the method includes intermittent activation of the venous-arterial reflex in the patient.
Citation Information
Patent Citations
Treatment of spasticity with intrathecal administration of dantrolene
JP2016539167A
Intravenous Baclofen Preparation and Treatment Method
JP2018502924A
Device and method for treating vascular and other diseases of extremities
US3465748A
Device for applying a pulsating pressure to a local region of the body and applications thereof
US7833179B2
Medical pressure therapy device and components thereof
WO2019064288A1
